Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China-Reference-Cited by-同舟云学术

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China

Published:2021-12 Issue:1 Volume:13 Page:107-116
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Zou Zihua¹^ORCID,Hao Xuezhi¹,Zhang Cuiying²,Li Haojing²,Dong Guilan³,Peng Yumei³,Ma Kewei⁴^ORCID,Guo Ye⁴,Shan Li⁵,Zhang Yan⁵,Liang Li⁶,Gu Yangchun⁶^ORCID,Xing Puyuan¹^ORCID,Li Junling¹^ORCID

Affiliation:

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Cancer Center, Inner Mongolia Autonomous Region People's Hospital Huhhot China

3. Oncology Department Tangshan People’ s Hospital Tangshan China

4. Cancer Center The First Hospital of Jilin University Changchun China

5. Department of Thoracic Oncology Tumor Hospital Affiliated to Xinjiang Medical University Urumqi China

6. Department of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14232

Reference20 articles.